Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Blosozumab

Copy Product Info
😃Good
Catalog No. T78278Cas No. 1132758-87-2
Alias TST-002, TST002, LY-2541546, LY2541546

Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.

Blosozumab

Blosozumab

Copy Product Info
😃Good
Catalog No. T78278Alias TST-002, TST002, LY-2541546, LY2541546Cas No. 1132758-87-2
Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$228-In Stock
5 mg$629-In Stock
10 mg$993-In Stock
25 mg$1,470-In Stock
50 mg$1,980-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.53% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.
In vivo
Blosozumab is a humanized monoclonal antibody (IgG4) that has been optimized for neutralizing the sclerosing protein. In 5 - and 6-month non-clinical safety studies in rats, Blosozumab resulted in a dose-dependent, reversible reduction in platelet counts, accompanied by accelerated platelet production, increased megakaryocyte growth, and altered megakaryocyte morphology. There was no change in platelet counts or megakaryocytes in cynomophagus monkeys treated with Blosozumab. [1]
SynonymsTST-002, TST002, LY-2541546, LY2541546
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetSOST/Sclerostin
Chemical Properties
Molecular Weight144.88 kDa
Cas No.1132758-87-2
Antibody Information
IsotypeHuman IgG4SP kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Blosozumab | purchase Blosozumab | Blosozumab cost | order Blosozumab | Blosozumab in vivo | Blosozumab molecular weight